Swarajya

Our View
MagazineHeadlinesVideosBooksस्वराज्यEconomyCultureEvents
User Profile
Subscribe
Swarajya
Subscribe
  • Our View
  • Headlines
  • Magazine
Swarajya
  • Politics
  • Economics
  • Business
  • Culture
  • Books & Ideas
  • World
  • Defence
  • Energy & Infrastructure
  • Science
  • Technology
  • Heritage
  • Videos
  • Archives
  • Blogs
  • News Brief
  • Subscriber login
  • Politics
  • Economics
  • Business
  • Culture
  • Books & Ideas
  • World
  • Defence
  • Energy & Infrastructure
  • Science
  • Technology
  • Heritage
  • Videos
  • Archives
  • Blogs
  • News Brief

CDSCO

Health Ministry Calls Media Report On Covid-19 Vaccine Side Effects 'Ill-Informed And Erroneous'
Health Ministry Calls Media Report On Covid-19 Vaccine Side Effects 'Ill-Informed And Erroneous'Swarajya StaffJan 17, 2023 03:33 PM +05:30 IST
CDSCO, State Drugs Administration Begin Joint Inspection Of Drug Manufacturing Units
CDSCO, State Drugs Administration Begin Joint Inspection Of Drug Manufacturing UnitsSwarajya StaffDec 27, 2022 04:13 PM +05:30 IST
Each Dose Of Covaxin, Covishield Likely To Be Capped At Rs 275 After Getting Regular Market Approval
Each Dose Of Covaxin, Covishield Likely To Be Capped At Rs 275 After Getting Regular Market ApprovalPTIJan 26, 2022 03:42 PM +05:30 IST
Guidelines On Covaxin For 15-18 Age Group Do Not Mention EUL By WHO: Govt Slams 'Ill-Informed, Misleading' Media Reports
Guidelines On Covaxin For 15-18 Age Group Do Not Mention EUL By WHO: Govt Slams 'Ill-Informed, Misleading' Media ReportsSwarajya StaffJan 7, 2022 03:32 PM +05:30 IST
India's First mRNA COVID Vaccine Candidate Found To Be Safe, Gets DCGI Nod For Phase 2/3 Clinical Trials
India's First mRNA COVID Vaccine Candidate Found To Be Safe, Gets DCGI Nod For Phase 2/3 Clinical TrialsSwarajya StaffAug 25, 2021 11:00 AM +05:30 IST
Govt's Expert Panel Likely To Take Up Applications For Three More COVID-19 Vaccines This Week
Govt's Expert Panel Likely To Take Up Applications For Three More COVID-19 Vaccines This WeekSwarajya StaffAug 17, 2021 08:45 AM +05:30 IST
US-Based Moderna Seeks DCGI Approval For Its mRNA COVID-19 Vaccine In India: Report
US-Based Moderna Seeks DCGI Approval For Its mRNA COVID-19 Vaccine In India: ReportSwarajya StaffJun 29, 2021 02:43 PM +05:30 IST
India's Drug Regulator Issues Guidelines To Clear Way For Import Of Foreign Produced COVID-19 Vaccines
India's Drug Regulator Issues Guidelines To Clear Way For Import Of Foreign Produced COVID-19 VaccinesSwarajya StaffMay 5, 2021 10:04 AM +05:30 IST
Hetero Gets DCGI's Expert Panel Nod To Conduct Phase 3 Trials Of Russian Sputnik V Covid Vaccine In India
Hetero Gets DCGI's Expert Panel Nod To Conduct Phase 3 Trials Of Russian Sputnik V Covid Vaccine In IndiaSwarajya StaffApr 30, 2021 10:24 AM +05:30 IST
Govt To Provide Import Licences, Registration Certificate For Foreign Vaccines Within Three Days Of Emergency Use Approval
Govt To Provide Import Licences, Registration Certificate For Foreign Vaccines Within Three Days Of Emergency Use ApprovalSwarajya StaffApr 16, 2021 09:57 AM +05:30 IST
Indian Drug Regulator's Expert Panel Recommends Phase 1 Trial Of Bharat Biotech's Intranasal Covid-19 Vaccine
Indian Drug Regulator's Expert Panel Recommends Phase 1 Trial Of Bharat Biotech's Intranasal Covid-19 VaccineIANSJan 20, 2021 09:19 AM +05:30 IST
COVAXIN: Bharat Biotech Again Applies For Emergency Use Approval Of Its Covid-19 Vaccine Candidate
COVAXIN: Bharat Biotech Again Applies For Emergency Use Approval Of Its Covid-19 Vaccine CandidateIANSDec 24, 2020 08:13 AM +05:30 IST
ICMR Gets CDSCO Approval For Clinical Trial Of Convalescent Plasma In Covid-19 Patients
ICMR Gets CDSCO Approval For Clinical Trial Of Convalescent Plasma In Covid-19 PatientsSwarajya StaffApr 18, 2020 01:38 PM +05:30 IST
One Each For Import And Export: How Over-Dependence On China And US Markets Blocks Indian Pharma’s Growth
One Each For Import And Export: How Over-Dependence On China And US Markets Blocks Indian Pharma’s Growth Karan BhasinApr 16, 2020 03:50 PM +05:30 IST
Load More

About Swarajya

Swarajya - a big tent for liberal right of centre discourse that reaches out, engages and caters to the new India.

editor@swarajyamag.com

Useful Links

  • About Us
  • Subscriptions Support
  • Editorial Philosophy
  • Press Kit
  • Fact Check
  • Gift Swarajya
  • Privacy Policy
  • Terms of Use
  • Code of Conduct
  • Plagiarism Policy
  • Refund & Cancellation Policy

Participate

  • Contact Us
  • Write for us
  • Style Guide
  • Advertise
  • Jobs

Stay Connected

  • Artboard 2 Copy 6Created with Sketch.Artboard 2 Copy 10Created with Sketch.Artboard 2 Copy 7Created with Sketch.Artboard 2 Copy 9Created with Sketch.
Copyright: Swarajya. All Rights Reserved.
Powered by Quintype